TREMFYA®: A Major Step for Psoriatic Arthritis!

Johnson & Johnson has announced groundbreaking new data in the treatment of Psoriatic Arthritis (PsA). TREMFYA® significantly inhibited the progression of structural damage by week 24 and maintained this effect up to week 48. These findings were presented at the Inflammatory Skin Diseases Summit (ISDS).

In the conducted Phase 3b APEX study, more than 50% of patients receiving TREMFYA® showed a 50% improvement in PsA symptoms by week 48. By week 24, patients treated with TREMFYA® inhibited structural damage in the joints 2.5 times more effectively than the placebo group.

Patients in the placebo group who switched to TREMFYA® treatment by week 24 showed a 57% reduction in the rate of joint damage. Dr. Christopher Ritchlin emphasized that PsA is a rapidly progressing disease if left untreated, highlighting that guselkumab can prevent this process.

TREMFYA® has demonstrated significant improvement in terms of the American College of Rheumatology response criteria (ACR50). ACR50 response rates increased in both the dosing groups given every 4 weeks and every 8 weeks. These data are consistent with the well-known safety profile of TREMFYA®.

Leonard Dragone stated that TREMFYA® is the only IL-23 inhibitor capable of preventing structural damage in active PsA. This treatment option offers an attractive first-line treatment opportunity for patients with psoriatic diseases.

TREMFYA® is a fully human monoclonal antibody that neutralizes inflammation at the cellular source by blocking IL-23 and binding to CD64 on the surface of IL-23 producing cells. Johnson & Johnson has also made an additional Biologics License Application to the FDA to present new data on preventing structural damage in patients with active PsA.